Godišnji-izvestaj Udruženja nefrologa Srbije-2011. godine

8/11/2019 Godinji-izvestaj Udruenja nefrologa Srbije-2011. godine

1/66

Serbian Society f Nephrology

, 2011

, 2011

, 2013.

ISSN 2217-9828


2/66

, 9

,

300

Roche d.o.o.,


3/66

.

.

. . . . - . . . . . . . . . . -

a . ,

. . ,


4/66


5/66


6/66

, 2011........................................7

...............................................................................................................................9

1. ......... 11

2.

2011. ......................................................................................12

3.

...............................................................................................134.

2011. .....................................15

5.

2011. ..................................................... ................... 20

6.

31. 2011..................................................................................26

7. 2011. ...........................................................33

8. ,

1997. 2011. .................................................................................... 35

2011. ....................................................39

1.

( )..................................................................................432. Ke 2011.

( )......................44

3. 2011. .........48

....................................................................................................................53


7/66


, 2011ANNUAL REPORT ON DIALYSIS

AND KIDNEY TRANSPLANTATION INSERBIA, 2011

, 2013.


8/66

:

.

.

.


9/66

-

2011.

.

2011. .

,

ERA-EDTA.

- ,

.

, ,

( ) . ,

,

.

, .

.

,

,

.

,

.

, 10. 2013.


10/66


11/66

, 2011

11

1.

.

1.

31.12. 2011.

Table 1. Number of dialysis and kidney transplantation centers in Serbia,

December 31st

2011 Treatment methods used

Number of centers

& y Hemodialysis & Peritoneal dialysis

29

Hemodialysis

29

Kidney transplantation

5

2011. 57 . -

-

2009. ,

. ,

.

2011. :

Medicon .

29 a, -

.

: , ,

,

.


12/66

, 2011

12

2011.

2011. 100%.

,

,

.

. , ERA-EDTA

15

.

,

.

: ( ),

( ), 2005-2008 ( )

*Method of data collection: aggregated data based on centre questionnaire (gray column), individual patient data (black

column), aggregated data collected retrospectively for the period 2005-2008 (white column)

1.

Figure 1. Response rate on the questionnaires sent to the centers for dialysis and kidney

transplantation

2.

0

20

40

60

80

100

1997 1998 1999 2000 2001 2002 2003 2004 2 005-8 2009 2010 2011

%


13/66

, 2011

13

1

. 1997. 2004.

, , 2005.

.

5 311. 2

19 (33%) 50 ,

150 6 (11%) .

2.

Figure 2. Distribution of centers according to number of patients on maintenance hemodilysis

and peritonal dialysis

2

. 2011.

2011.

.

3.

19

22

10

3 3

0

5

10

15

20

25

200


14/66

, 2011

14

2.

2011. 2011.

Table 2.Number of patients on maintenance hemodialysis (HD) and peritoneal dialysis (PD) on

December 31st

2011, number of patients started hemodialysis and peritoneal dialysis in 2011

(HD)

(PD)

31.12.2011.

2011.

New in

2011

31.12. 2011. 2011.

New in 2011

1 A 14 1 0 02 51 12 0 03 , 33 2 0 04 , 95 11 18 15 , 8 2 6 36 , 245 46 66 157 , 80 24 13 38 , 130 3 74 189 , 88 13 0 010 ,Medicon 38 11 0 011 , 66 5 0 012 , 46 7 0 013 , FMC, 86 2 0 014 , FMC,. 81 33 0 015 , FMC, 64 4 0 016 24 5 1 017 96 18 16 418 117 26 0 019 47 8 0 020 55 12 1 021 7 0 0 0

22 68 12 7 323 101 21 1 124 76 13 3 025 13 0 0 026 29 10 2 127 , 138 17 41 1128 87 12 2 029 119 17 2 030 11 4 3 031 96 27 27 632 79 13 0 033 24 6 1 034 , 5 1 0 035 , 191 49 47 636 , FMC 22 0 0 0

37 91 19 2 038 , 121 33 17 739 , FMC 92 9 0 040 116 21 0 041 52 13 9 242 124 22 0 043 26 12 0 044 50 12 2 245 8 3 0 046 11 2 0 047 85 17 0 048 50 4 4 149 86 9 0 050 164 40 0 051 62 9 13 452 157 35 2 053 84 14 10 454 76 26 1 055 104 16 4 456 Ho ,Medicon 6 4 0 059 15 4 0 0


15/66

, 2011

15

2011. ,

Medicon

.

2011. 2010.

(78,1%

, 7,8% ).

ERA-EDTA.

(3,7%), (11,3%) [1].

10-20% , 20% ,

10-20% 20% .

29 ,

14 , .

, ,

8 58 , 1%

.

(CAPD),

(APD).

2011.

2011.

ERA-EDTA .

, -

, -

.

4.


16/66

, 2011

16

, (,

),

.

ERA-EDTA -

.

ERA-EDTA -

91. .

(, -

pre-emptive kidney transplantation).

91.

.

.

3 -

2011. : 2011.

, 31. 2011. ,

2011.

2011. .

3.

2011.

Table 3. Main epidemiological data of patients on renal replacement therapy in

Serbia in 2011

1.

Number of new patients,

at day 1

31. 12. 2011.

Number of patients

Dec31st2011

2011. .

Number of patients

died 2011

O

( )

General population

(in thousands)

1043 5275 774 7259

4

2011.


17/66

, 2011

17

91. , 5

31. 2011.

.

4. 2011.

91.

Table 4. Data on patients who started renal replacement therapy in Serbia in 2011 and were on

the therapy at day 91

Hemodialysis

Peritoneal

dialysis

idnytransplantation

Total

(%) 91. .Number (%) of new patients,at day 91

847(88,2)

100(10,4)

13(1,4)

960(100)

91. Number of patientsper milion populationat day 91

116,7 13,8 1,8 132,3

3 4

2011. 1043, 90

960 . 83 2011.

, 90 (8%)

. ERA-EDTA

91.

2% 17% ( , ) [1].

2011. 91. (960), 847 (88,2%)

, 100 (10,4%) ,

13 (1,4%) ( 4).

2011. -

5275 : 4119 (78 %), -

414 (8%), -

738 (14 %) ( 5). 4

.


18/66

, 2011

18

5.

31. 2011.

Table 5. Data on renal replacement therapy patients in Serbia on December 31st2011

Hemodialysis

Peritoneal

dialysis

idnytransplantation

Total

(%) 31.12. 2011. Number (%) of patientsDec31st2011

4119(78)

414(8)

738(14)

5275(100)

31.12. 2011. Number of patientsper milion populationDec 31st2011

568 57 102 727

2011. -

: 2010. 5546, 2011. 5275,

. ,

2011. . -

-

. ,

2011. , -

, -

.

2011.

2010. ( 468 414), 2010. 2009. ( 504 468).

-

/

.

-

, , ,

.

2010. 31. 997 , 2011. 738.


19/66

, 2011

19

.

, .

.

2011. 772 , 90 2010.

.

741 688, 106 79,

2010.

10 5.

,

. -

, ,

.

3 -

1997. 2011. .

.

- (hemodialysis); - (peritoneal dialysis); -

(kidney transplantation)

3.

1997 2011.

Figure 3. Distribution of patients according to the method of renal replacement therapy in our

country during the period 1997 2011

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

1997 1998 1999 2000 2001 2002 2003 2004 2008 2009 2010 2011

T


20/66

, 2011

20

ERA-EDTA 2010.

2011. ,

,

.

, -

40%

, [1,2].

2011.

2011. e 1043

.

(60,5 vs.58,8 ).

, 2011. ,

6.

6.

2010.

Table 6. Data on patients started renal replacement therapy in 2010

All patients

Males

Females

NumberIncidence

Mean ge

NumberIncidence

Mean ge

NumberIncidence

Mean ge

, New patients atday 1

1043 60,514,5 637 60,514,3 406 60,514,9

Incidence pmp atday 1

143,7 180,4 108,9

, 91. New patients atday 91

960 59,514,5 592 60,014,3 368 59,815,0

91. Incidence pmp atday 91

132,3 167,7 98,7

5.


21/66

, 2011

21

,

(1043 1420 ), (143,7

. 188,6 ).

91. (

4). 2011.

,

, .

4.

91.

Figure 4.Incidence rate of renal replacement therapy patients per million population (pmp)

at day 1 and 91

4 2005. 2010.

91.

43 62 ,

91. 2435%. 2011.

83 ,

8,0%.

91. .

-

, . , -

-

0

20

40

60

80

100

120

140

160

180

200

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

pmp

1. 91.


22/66

, 2011

22

-

. ,

91. -

ERA-EDTA[1,2].

5. 91.

Figure 5. Distribution of patients on renal replacement therapy at day 91 according to ageand gender

5

91.

. .

.

6574 , 75

( 426 146

).

0

50

100

150

200

250

300

350

400

450

500

0-19 20-44 45-64 65-74 75+

pmp


23/66

, 2011

23

7.

2011.

91.

( ) Table 7. Causes of end-stage renal disease in all patients started renal replacement therapy in

2011 and those on treatmentat day 91 presented as incidence rate (pmp) and percent

Diagnosis

1.

at day 1

91.

at day 91

I/pmp % I/mp %

Glomerulonephritis

13,5 9,4 13,2 10,0

Pyelonephritis

16,3 11,3 13,9 10,5

Balkan nephropathy

3,2 2,2 - -

Polycystic kidney disease

8,8 6,1 8,5 6,5

Diabetes

31,3 21,8 30,0 22,7

Hypertension

36,2 25,2 34,4 26,0

Renovascular disease

0,4 0,3 0,4 0,3

Miscellaneous

20,6 14,3 19,8 15,0

Unknown

13,4 9,3 11,8 9,0

2011. (Ta 7),

.

2011.

.

2011.

,

ERA-EDTA. ( ) -

39,4% [1]. ERA-EDTA -

, -


24/66

, 2011

24

,

[1-3].

.

-

, ,

.

6.

91. (

91. )

Figure 6. Methods of renal replacement therapy used in new patients at day 91 (presented as

percentages of total number of patients regisetred at day 91)

6

91. .

2009. 2011. ,

-

4%.

,

. 1,3% -

,

2,1% (, ) 15,9% ().

81

0.4

6.8

0.4

10

1.1 0.2

0

10

20

30

40

50

60

70

80

90

HD-

centar

HD-kua HDF APD CAPD Tx-ivi

dav.

Tx-kad.

%


25/66


26/66

, 2011

26

31. 2011.

31. 2011.

.

8.

31. 2011.

Table 8. Data on patients on renal replacement therapy in Serbia on December 31. 2011

All patients

Males

Females

Number

(Prevalence, pmp)

,

Age, years

Number

(Prevalence,pmp)

,

Age, years

Number

(Prevalence,pmp)

,

Age, years

5275(726,7)

57,014,3 3143(887,6)

57,014,2 2141(574,3)

57,114,5

- 2011. 727 ( 8).

ERA-EDTA

2011. 802 ()

1271 (, ) -

[1], 2010. 1752 -

[4]. A

ERA-EDTA 2011. 705

624 [1].

1997,

,

2010. . 1997. 435

305

2010. ( 9).

2011. -

, .

6.


27/66

, 2011

27

8 2011.

(59,5%) (40,5%),

2011. .

ERA-EDTA [1]. -

2011. 57

, 5,5 1999. [5].

ERA-EDTA 2011.

55 () 65,1 (,

) [1].

8.

31.

Figure 8. Distribution of patients on renal replacement therapy in Serbia on December 31st

according to age and gender

31. 2011.

.

8 .

6574 , 918

75 .

19 , ,

.

0

500

1000

1500

2000

2500

0-19 20-44 45-64 65-74 75+

pmp


28/66

, 2011

28

9

1997-2011.

Table9.E

pidemiologicaldataonend-stagerenaldiseasepatientsinourcountryfrom1997-2011

.

RR

POP

Ni

Ni/P

No

No/P

Ns

Ns/P

(Ni-No)/P

Ki

Ko

Klinear

1997

92,6

10,6

1149

108

953

90

4615

435

18,5

24,4

20,7

4,2

1998

93,9

8,5

1042

123

680

80

3785

445

42,6

27,5

17,9

9,6

1999

92

8,5

958

113

677

80

3604

424

33

26,5

18.8

7.7

2000

92,3

8,5

985

116

689

81

3961

466

34,8

24,9

17,4

7,5

2001

96,2

8,5

977

115

736

87

4224

497

28,3

23,1

17,4

5,7

2002

90,4

8,5

1112

137

783

96

3997

492

40,7

27,8

19,6

8,2

2003

60,2

8,5

573

117

2398

491

23,8

2004

83,0

8,5

635

95

2700

402

23,6

2005

71,7

7,4

1150

167

563

82

3530

512

79,3

33,5

16,3

17,2

2006

71,7

7,4

1093

158

662

96

3689

535

58,2

30,5

18,5

12,0

2007

71,7

7,4

1208

175

635

92

3990

578

77,4

31,2

16,4

14,8

2008

73,9

7,6

1349

178

636

97

4493

686

93,8

30,1

14,6

15,5

2009

100

7,5

1332

179

871

116

5208

699

61,5

25,6

16,7

8,9

2010

100

7,5

1420

189

862

115

5546

740

74,4

25,6

15,5

10,1

2011

100

7,3

1043

144

774

106

5275

727

41,0

19,8

14,7

5,1

RR=

POP=

Ni=

Ni/P=

No=

No/P=

Ns=

31.

Ns/P=

(Ni-No)/P=

Ki=

Ko=No/Ns()

Klinear=KiK

o


29/66

, 2011

29

10.

31. 2011. e

able 10. Frequency of end-stage renal disease causes in patients on renal replacement therapy

on December 31st

2011Diagnosis

Prevalence,pmp

%

Glomerulonephritis

153,6 21,1

Pyelonephritis

85,0 11,7

Balkan nephropathy

34,5 4,7

Polycystic kidney disease 51,7 7,1

Diabetes

95,1 13,1

Hypertension

170,3 23,4

Renovascular disease

7,9 1,1

Miscellaneous

86,0 11,8

Unknown

42,7 5,9

10

-

31. 2011. e.

.

.

, [4],

[1].

.

2009.

137,7

, 32,6 2011.

. -

.


30/66

, 2011

30

,

( 10, 9).

,

.

.

10 ,

ERA-EDTA

. -

, -

.

: 37,9 -

2009. , 31,6 2010. 34,5

2011. .

(Glomerulonephritis); (Pyelonephritis); (Balkan nephropathy); (Polycystic kidney disease); (Diabeltes mellitus); (Hypertension)

9.

2000. 2011.

( 31. )

Figure 9. Frequency of end-stage renal disease causes in patients on renal replacement therapy

in 2000 and 2011 (on December 31)

0

5

10

15

20

25

30

%

2000 2011


31/66

, 2011

31

9 -

-

31. 2000. 2011. .

.

-

, -

. ,

. ,

,

. , , -

[6,7].

10.

31. 2011.

Figure 10. Percent of established renal replacement therapy methods in prevalent patients on

December 31st2011.

2011. -

o (333063,1%),

754 (14,3%) ( 10).

413 (7,9%)

(3997,6%).

2011. 14%

63.1

0.6

14.3

0.3

7.6 9.5

4.5

0

10

20

30

40

50

60

HD-centar HD-kua HDF APD CAPD Tx-ivi

davalac

Tx-kadaver.

Davalac

%


32/66

, 2011

32

,

. -

40%

,

(61.8%) (71,9%).

6,6% 34,4%,

[1,8].

- (hemodialysis); - (peritoneal dialysis);

- (kidney transplantation)

11.

91.

Figure 11.Distribution of patients on established renal replacement therapy methods at day 91

according to age

c

2011.

( 11).X

,

. , , -

2044

.

0

20

40

60

80

100

0-19 20-44 45-64 65-74 75+

%


33/66

, 2011

33

2011.

2011. o 113 ,

44 (38,9%) , 69 (61,13%)

. 2011.

. 13,4 ( -

) 2010. 15,6 -

2011.. ,

2011.

(69 44) ( 11).

11.Te 2011.

Table 11. Kidney transplantations performed in 2011

Total

Living

Related

Unrelated

Type unknown

Deceased

(%)Number (%)

113 28 (24,8%) 3 (2,7%) 13 (11,5%) 69 (61,1%)

/Number pmp

15,6 3,9 0,4 1,8 9,5

11 13

.

13 , 2011. -

, 20 ERA-EDTA

. ,

(21), (22)

.

ERA-EDTA,

20, ., ,

.

7.


34/66

, 2011

34

12., 31. 2011.

Table 12. Number, percentage and prevalence of patients with functional kidney graft on

December 31st

2011

Donor

TotalLiving

Deceased

Type unknown

(%)Number (%)

501 (67,9%) 237 (32,1%) 0 (0%) 738 (100%)

Prevalence, pmp

71,7 31,6 0 103,3

31. 2011. 738

501 (67.9%)

, 237 (32.1%) ( 12).

12.

1997. 2011.

Figure 12.tal number of patients with transplanted kidney in period 1997- 2011 and number

of patients transplanted in presented years

-

2011. 259 2010. (738 -

997) ( 12). ,

. ,

0

200

400

600

800

1000

1200

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011


35/66

, 2011

35

2011. -

. -

, -

.

, 1997. 2011.

13

1997. 2011. .

1997. 2005. 108 167

, 2010. .

[9-11].

,

, , - .

13.K

1997. 2004.

2005. 2011.

Figure 13. Changes in incidence and prevalence of renal replacement therapy patients in ourcountry from 1997 to 2011

8.

0

100

200

300

400

500

600

700

800

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

pmp


36/66


37/66

, 2011

37

15. (%)

o 1997. 2011.

Figure 15. Mortality (%) of patients on renal replacement therapy from 1997 to 2011

-

. , 2011.

. ,

-

, -

.

16. 2011.

31. 2011

Figure 16. Mortality calculated as percent of patients died in 2011 from the total number of renal

replacement therapy ptients on Decembar 31 2011 in relation of established therapy

20.7

17.9 18.8

17.4 17.4

19.6

16.3

18.5

16.414.6

16.8 15.514.7

0

5

10

15

20

25

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

%

16.6

19.8

1.0

14.7

0

5

10

15

20

25

.

%


38/66

, 2011

38

16

, 31. 2011.

.

2010. ,

, 2011. .

- (cardiovascular diseases); - (cerebrovascular diseases); - (gastrointestinal diseases)

17.

2011.

Figure 17. Causes of death of renal replacement therapy ptients in 2011

17

2011. . -

, ,

-

.

, 6,7% -

.

.

. 2011. 414 -

113 , 34

, -

.

37.8

17.4

6.2

9.1

3.6

10.1

14.5

0 5 10 15 20 25 30 35 40

%


39/66

, 2011

39

.

. 2011.

, 2001.

[12] 18.

- (hemodialysis); - (peritoneal dialysis);

- (kidney transplantation)

18.

2011.

Figure 18. Percentage of hepatitis B and hepatitis C positive patients treated with renal

replacement therapy in Serbia in 2011

18

.

2001. 2011. .

,

anti-HCV .

0

5

10

15

20

25

30

HD PD Tx

HBV 2001

HBV 2011

HCV 2001

HCV 2011


40/66

, 2011

40

ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2011. Academic1.

Medical Center, Department of Medical Informatics, Amsterdam, The

Netherlands, 2013.

ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2010. Academic2.

Medical Center, Department of Medical Informatics, Amsterdam, The

Netherlands, 2012.

ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2008. Academic Medical3.

Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2010

U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic4.

Kidney Disease and End-Stage Renal Disease in the United States, NationalInstitutes of Health, National Institute of Diabetes and Digestive and Kidney

Diseases, Bethesda, MD, 2012.

Djukanovi L, Aksi-Milievi B, Anti M, et al. Epidemiology of end-stage renal5.

disease and hemodialysis treatment in Serbia at the turn of the millennium.

Hemodial Int 2012;16:517525

Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage6.

renal disease due to hypertension. Am J Kidney Dis 1994;23:655660.

Zucchelli P, Zuccala A. Can we accurately diagnose nephrosclerosis? Nephrol7.

Dial Transplant 1995;10 [Suppl 6]:25.ERA-EDTA Registry: ERA-EDTA Registry 2003 Annual Report. Academic8.

Medical Center, Amsterdam, The Netherlands, May 2005.

Kramer , Stel V, Zoccali C, et al. An update on renal replacement therapy in9.

Europe: ERAEDTA Registry data from 1997 to 2006. Nephrol Dial Transplant

2009;24:35573566.

Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al.10.

United States Renal Data System 2011 Annual Data Report: Atlas of chronic

kidney disease & end-stage renal disease in the United States. Am J Kidney Dis.

2012;59(1 Suppl 1):A7, e1420.

Stewart JH, McCredie MR, Williams SM. Geographic, ethnic, age related and11.

temporal variation in the incidence of end-stage renal disease in Europe, Canada

and the Asia-Pacic region, 19982002. Nephrol Dial Transplant2006;21:2178

2183.

Djukanovi Lj, Radovi M. Godinji izvetaj o leenju dijalizama i transplan-12.

tacijom bubrega u Jugoslaviji, 2001. Beograd: KC Srbije; 2003.


41/66


, 2011

ANNUAL REPORT ON VASCULAR ACCESS

FOR HEMODIALYSIS IN

SERBIA, 2011

, 2013.


42/66

e

.


43/66

, 2011

43

( )

57 , -

2011. 53 . -

, ,

94,7% e

83,6%.

4171 3249 (92,7%) -

,

(91,9%).

(3,2% 3,8%)

(4,1% 4,3%) -

. -

( 1).

1.

31. 2011.

Table 1. Prevalence of certain types of vascular access in patients treated with hemodalysis in

Serbia on 31stDecember 2011

Vascular Access

(%)Number (%)

Arteriovenous stula

3868 (92.7%)

Vascular Graft

/Arm 87 (2,1%)

/Leg 45 (1,1%)

/Overall 132 (3,2%)

()Vascular Catheters (VC)

-/ VC-J 67 (1,6%)

-/VC-SC 91 (2,2%)

-/VC-F 13 (0,3%)

/Overall 171 (4,1%)

Vascular Access, Overall

4171 (100%)

-= , -K =

-= VC-J= vascular catheter, jugular, VC-SC= vascular catheter, subclavian, VC-F=vascular catheter, femoral

1.


44/66

, 2011

44

The Dialysis Outcomes and Practice Patterns Study - DOPPS III

, - 50% -

, 70% 47%

[1].

91% .

(,Fistula first)

32% 2003.

60,6% 2012. [2].

KE 2011. ( )

, -

. ,

, o ( ) ,

.

1.

Figure 1. Dialysis centers that create the greatest number of vascular access with a number of

referral centers

2011.

, , ,

2.


45/66

, 2011

45

.

( 2).

( , , ),

-

, .

, ,

,

.

2.

2011.

Table 2. Number of particular vascular access created in referent centers in 2011

Center

Overall

AVF

AVG

arm

AVGleg

-VC-J

-VC-SC

-VC-F

Preemptive

AVF

267 165 35 8 29 9 21 2

259 250 7 2 28

172 145 3 2 22 24

113 109 3 1 7

106 104 2 14

76 71 3 1 1 11

64 64 24

62 61 1 1# 59 55 3 1 7

* 44 42 1 1 22

.

44 40 2 2 13

# 40 39 1 8

32 23 9 1

32 31 1 6

31 23 8 11

# 29 29 3

20 19 1 4

18 18 2


46/66

, 2011

46

.

17 3 13 1

16 16 8

15 13 1 1 1

15 15

13 13 2

12 12 0

10 10 1

6 6 3

2 2

,

(%)Overall,No(%)

1574(100)

1378(87,6)

67(4,3)

16(1,0)

65(4,1)

26(1,6)

22(1,4)

203(14,7)

-= , -K = -= VC-J= vascular catheter, jugular, CV-SC= vascular catheter, subclavian,VC-F=vascular catheter, femoral# *

,

(87,6%)

(5,3%) (7,1%) (-

2).

, -

.

,

-VascularAccess Society [3] -

.

, 83 (5,3%),

(4,3%), (3,3%). O

u 2011. 14,7% je -

, (7,3%).

, -

.


47/66

, 2011

47

A- (arteriovenous stula), = (vascular catheter, jugular)r, = (vascular catheter, subclavian),- (vascular catheter, femoral)

2. 2011.

Figure 2. The number and type of vascular access created in Serbia in 2011

2

.

3, 31 (59%)

. , 29 ,

( ).

. 7 , 14% 10

. , , .

,

.


48/66

, 2011

48

3. (%)

Figure 3.Number (%) of dialysis centers that create pre-emptive arteriovenous stula

2011.

2011. (1021),

663

(65%) ( 4).

4. (%)

2011. , ()

Figure 4.Number (%) of incident patients who started hemodialysis with/without vascular

catheter () in 2011

0 10

15 (30%) 29 (56%)

7 (14%)

663 (64%)

358 (36%)

3.

= ca ,with vascular catheter

= ,without vascular catheter


49/66

, 2011

49

32

( 32 ).

8 , 4 .

,

.

5. (%)

Figure 5.Number (%) of centers that set temporary vascular catheters for hemodialysis

= (vascular catheter, jugular),= (vascular catheter, subclavian),= (vascular catheter, femora)l

6. Figure 6. Localization of temporary vascular catheters for hemodialysis


50/66

, 2011

50

, 2011.

(97% ).

(66% 60%),

(59% 73%),

( 6).

,

.

= (vascular catheter, jugular),= (vascular catheter, subclavian), = (vascular catheter, femoral)

7. (%)

Figure 7. Number (%) of temporary vascular catheters that are used as permanent vascularaccess for hemodialysis

- Vascular Ac-

cess Society ( 10.4) [3], -

-

( 152 ). ,

(60%), (31%)

(9%), 7. -

,

- ,

.


51/66

, 2011

51

1. Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ,

Pisoni RL. Vascular access use and outcomes: an international perspective fromthe Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant.

2008; 23(10): 3219-3226.

2. http://www.stularst.org, About Fistula First, Fistula First Catheter Last (FF/

CL) Data, July 2003 April 2012 Graphs, Graphs of Prevalent AV Fistula Use

Rates, By Network. Accessed on September 9, 2013.

3. http://www.vascularaccesssociety.com Vascular Access Society, Home Page,

Guidelines, 10. Central venous access, Guidelines 10.3. Accessed on September

10, 2013.


52/66


53/66


54/66


55/66

55

:

:

: :

: :34300

: 069 8166 766 : 034 713 262

E-mail: [email protected]

:

:

: O

:

: I 26 :21400

: 021 750 380 : 021 751 105


:

:

:

: . : 2 :11000

: 011 366 2421 : 011 361 7127


:

:

:

: . : 10 :11000

: 011 206 0765 : 011 3612 858


:

: -

:

: .

: 161 :11000

: 011 381 0458 : 011 3806977

E-mail: [email protected];[email protected]


56/66

56

:

:

:

: . .

: 17 :11000

: 011 266 2502 : 011 266 2502


:

: K-

: ,

: -: 9 :11080

: 011 3772 722 : 011 3772 758


:

:

: .

: 27 :11550: 011 8120 164 : 011 8123 173

E-mail: [email protected] nefropatija@ absolutok.net

:

: ,

:

:

: 91 :11460

: 011 7872 111 : 011 8300 182


:

:

:

: .

: 2 :11400

: 011 8231 988 : 011 8230 161E-mail: [email protected]


57/66

57

:

:

:

: 231 :11500

: 011 8721 560 : 011 8123 560


:

: Medicon

: . -

: 17 :11070: 011 313 10 32 : 011 313 10 27


:

: . Fresenius Medical Care

: .

: 11 :11000


:


: .

: 63 :11000

: 011 2444 333 : 011 245 9040


: -


: ,

: 11 :11070

: 011 2280 522 : 011 2289 712

E-mail: veselin.skataric@ fmc-ag.com


58/66

58

:

:

:

:

: 1 :19210

T: 030 422 777 . 251 :030-435 228


:

:

: -

: : :14000

: 014 295 288 : 014 221 330


:

:

:

: . : . . 1 :17500

: 017 427 044 : 017 405 126


:

:

:

:

: :21460

: 021 7954 507 :


:

:

:

:

: .. :26300

: 013 832 271 : 013 833 124



59/66

59

:

:

:

: : :12320

: 012 643 140 : 012 643 144


:

: : ,

: . : :19000

: 019 445 646 : 019 420 672


:

:

: ,

: .

: 5 :23000

: 023 513 390 : 023 513 374


:

: O

: -

:

: 110 :23300: 0230 434 603 : 0230 422 513


:

:

:

: 1-3 :19320: 019 801 455 : 019 802 851

E-mail:[email protected]


60/66

60

:

:

:

:

: 10 :38220

: 028 423 994 : 028 425 546E-mail: zcentarkm@ open.telekom.rs

:

:

: ,

: : 30 :34000

: 034 370 302, 034 50 52 26 : 034 370 302


:

:

: : :36000

: 036 301 872 :


:

:

`: -

:

: 16 :37000

: 037 414 097 : 037 424 039


:

:

:

: 2 : 027 385160: 027 -381 335 : 027 -381 595



61/66

61

:

:

:

: . , mr sc

: K 9 :16000

: 016 -252 500 : 016 344 4 501


:

: .

`: ,

: . : 65 :15300

: 015 873 333 : 015 873 344


:

:

:

: -: 4 :19300

: 019 542 951 : 019 544 296

E-mial: [email protected]

:

:

:

: .

: 48 :18000

: 018 4530 856 : 018 530 127


:

:

:

:

: :18000: 018 508 919 :

E-mial: [email protected]


62/66

62

:


:

: 94 :18000

: 018 207 713 : 018 207-710


:

:

: , dr sc

: 1 :36300: 020 321 296 : 020-311-764


:

:

:

: .

: 1-3 :21000: 021 484 3984 :


:

: . Medicon

:

: 11, . 42 :21000: 021 545 060 : 021 545 060


:


: , dr sc

: 2 :21000

: 021 4791 400 : 021 6312 323



63/66

63

:

:

:

:

: 11 : 26000

: 013 319 900 : 0013 317 956


:

:

: -: :18300

: 010 305 283 : 010 305 349


:

:

:

: . .: 135 :12000

: 012 550 222 : 012 550 585


:

: ,

: O

:

: 1 :31300

: 033 712 975 : 033 714 166


:

:

:

:

: 2 :18400: 027 324 000 . 106 : 027 324 762



64/66

64

:

:

: ,

:

: 64 :24400

: 024 815 111 :


:

: ,

:

: : 10 :36310


:

:

: ,

: : 51 :11300

: 026 223 522 / 161 : 026 221 346


:

:

: .

: 147 :11420

: 026/330-319 : 026 313 075


:

:

:

:

: 75 :25000: 025 467 878 :



65/66


66/66

Documents

Godišnji-izvestaj Udruženja nefrologa Srbije-2011. godine